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Abstract
Objectives:  The  goals  of  this  study  were  to  assess  the  diagnostic  accuracy  of  shear  wave  elas-
tography (SWE)  using  the  results  of  histopathological  analysis  as  a  standard  of  reference  and
compare the  results  of  SWE  and  those  of  transient  elastography  (TE)  to  the  degree  of  ﬁbrosis
as evaluated  by  histomorphometry.
Patients  and  methods:  Adult  patients  who  were  scheduled  to  undergo  liver  biopsy  were  prospec-
tively enrolled  in  the  study.  The  diagnostic  performances  of  SWE  were  assessed  using  AUROC
curve analysis  according  to  ﬁbrosis  thresholds  deﬁned  by  ≥  F2  (signiﬁcant  ﬁbrosis),  ≥  F3
(advanced  ﬁbrosis)  and  F4  (cirrhosis).  Additional  analyses  using  the  Obuchowski  measures  for
pairwise comparisons  of  ﬁbrosis  stages  were  performed.  In  a  subgroup  of  55  patients,  the  rela-
tionships  between  stiffness  as  measured  using  SWE  and  TE  and  the  percentage  of  ﬁbrosis  were
compared using  Spearman’s  rank  coefﬁcient.
Abbreviations: SWE, shear wave elastography; TE, transient elastography; (w)AUROC, (weighted) area under the receiver operating
characteristic; CI, conﬁdence interval; ARFI, acoustic radiation force impulse; HBV, hepatitis B virus; HCV, hepatitis C virus; BMI, body
mass index; ROI, region of interest; kPa, kilopascals; ICC, intra-class correlation coefﬁcient; IQR, inter-quartile range; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase.
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Results:  Among  the  initially  enrolled  170  patients,  148/170  (87%)  had  successful  SWE  acquisi-
tion and  formed  the  study  population.  SWE  sensitivity  and  speciﬁcity  were  respectively  85.1%
and 82.7%  (≥  F2),  88.9%  and  90.3%  (≥  F3),  93.3%  and  98.3%  (F4).  The  AUROC  curves  of  SWE
along with  their  95%  conﬁdence  intervals  (CI)  were  respectively  0.904  (95%CI:  0.845—0.946)
for ﬁbrosis  ≥  F2;  0.958  (95%CI:  0.912—0.984)  for  ﬁbrosis  ≥  F3  and  0.988  (95%CI:  0.955—0.999)
for ﬁbrosis  =  F4.  The  global  Obuchowski  measure  was  0.953  ±  0.007.  In  the  subgroup  study,  a
signiﬁcant  correlation  was  found  between  the  percentage  of  ﬁbrosis  and  stiffness  as  assessed
by SWE  (r  =  0.77;  95%CI:  0.63—0.86;  P  <  0.0001)  and  by  TE  (r  =  0.65;  95%CI:  0.47—0.78;  P  <  0.01).
Conclusion:  SWE  is  accurate  to  assess  liver  ﬁbrosis  in  patients  with  chronic  liver  disease.
© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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lhronic  liver  diseases  are  major  public  health  concerns,  with
n  estimated  mortality  of  1.5  million  per  year  worldwide  due
o  cirrhosis  and  its  complications  [1].  The  assessment  of  liver
brosis  is  a  key  element  to  determine  prognosis,  to  man-
ge  treatment,  to  monitor  disease  progression  and  assess
esponse  to  therapy  in  patients  with  chronic  liver  disease.
istopathological  assessment  using  liver  biopsy  remains  the
tandard  of  reference  to  evaluate  liver  ﬁbrosis.  However,
his  procedure  is  painful  and  may  lead  to  hemorrhage  (0.3%)
r  death  (0.01%).  In  addition,  the  biopsy  analysis  depends
n  the  experience  of  the  pathologist,  the  size  of  the  biopsy
ample  (usually  about  1/50,000  of  the  total  liver  mass)  and
he  site  of  sampling  [2].  The  heterogeneous  distribution  of
iver  ﬁbrosis  as  well  as  intra-  and  inter-observer  variability
xplain  why  the  diagnosis  of  cirrhosis  can  be  missed  in  up  to
0%  [3].
To  address  these  limitations,  non-invasive  methods  have
een  investigated  for  estimating  liver  ﬁbrosis  in  patients
ith  chronic  liver  diseases.  Among  the  available  non-
nvasive  approaches  shear  wave-based  techniques  such  as
ibroScan®,  also  named  transient  elastography  (TE),  or
coustic  radiation  force  impulse  (ARFI)  have  been  developed
4].  With  TE,  liver  stiffness  is  assessed  by  estimating  the
peed  of  shear  waves  mechanically  generated  at  the  surface
f  the  skin.  Several  studies  have  reported  good  perform-
nces  of  TE  in  patients  with  speciﬁc  causes  of  liver  ﬁbrosis
hepatitis  C  virus  [HCV]  or  hepatitis  B  virus  [HBV]  infections,
lcoholic  liver  disease  [5],  non-alcoholic  steatohepatitis,
on-alcoholic  fatty  liver  disease  [6],  primary  biliary  cirrhosis
r  primary  sclerosing  cholangitis)  [7].  However,  TE  does  not
llow  measuring  stiffness  in  patients  with  ascites  and  fails  in
p  to  20%,  particularly  when  body  mass  index  (BMI)  is  high
8].  ARFI  has  the  advantage  to  provide  a  steerable  point
stimate  of  liver  tissue  stiffness,  which  can  be  guided  by
ltrasound.  When  compared  to  the  results  of  histopatholog-
cal  analysis,  both  techniques  have  shown  similar  diagnostic
erformances  [6,9,10].
Shear  wave  elastography  (SWE),  also  named  supersonic
hear  imaging  or  two-dimensional  (2D)  SWE,  implemented
n  the  Aixplorer® unit  (SuperSonic  Imagine,  Aix-en-
rovence,  France)  provides  in  real-time,  a  2D  quantitative
ap  of  tissue  stiffness,  that  can  be  used  in  several  organs11,12].  This  image  enables  adjustment  of  the  region  of
nterest  (ROI)  to  assess  a  region  of  tissue  (up  to  4  cm  long,
 cm  wide),  to  perform  the  measurements  while  assessing
rtifacts  from  tissue  movement  pulsation  around  larger
T
t
p
eessels  and  reverberation  under  the  liver  capsule  [13].  In
CV-  and  HBV-infected  patients,  SWE  allows  assessment  of
evere  ﬁbrosis  and  cirrhosis  as  accurately  as  TE  does  with
etter  diagnostic  performances  in  livers  with  signiﬁcant
brosis  [14,15].
The  main  objective  of  this  study  was  to  evaluate  the
iagnostic  accuracy  of  SWE  compared  to  the  results  of  liver
iopsy.  We  also  assessed  the  relationships  between  stiffness
nd  METAVIR  ﬁbrosis  scores,  METAVIR  activity  and  steatosis
s  well  as  the  inter-observer  reproducibility  of  SWE.  In  a  sub-
roup  of  patients,  we  compared  the  diagnostic  accuracy  of
WE  and  TE  according  to  ﬁbrosis  thresholds  and  assessed  the
elationships  between  stiffness  measured  by  SWE  or  TE  and
he  percentage  of  ﬁbrosis,  evaluated  by  histomorphometry.
aterials and methods
tudy population
ll  consecutive  patients  were  eligible  if  they  were  at  least
8  year  old,  if  they  were  scheduled  to  undergo  liver  biopsy
hatever  its  indication  in  the  Department  of  Radiology
t  Lyon  Hospitals  (France)  from  September  2010  to  May
012.  Exclusion  criteria  were  a  liver  transplantation  for
ess  than  6  months  or  contra-indications  for  liver  biopsy
marked  coagulation  abnormalities,  anticoagulant  therapy,
ardiac  insufﬁciency,  ascites,  acute  liver  disease).  This
tudy  protocol  conformed  to  the  ethical  guidelines  of  the
975  declaration  of  Helsinki.  Informed  written  consent  was
btained  from  each  patient.
tudy procedures
fter  a  6-hour  fasting  period,  venous  blood  samples  were
ollected  to  assess  liver  function.  A  standard  Doppler  ultra-
ound  examination  was  then  performed  to  identify  the
ite  of  biopsy  and  to  perform  SWE.  An  ultrasound  machine
ixplorer® (SuperSonic  Imagine,  Aix-en-Provence,  France)
ith  the  low  frequency  convex  probe  (SC6-1)  suitable  for
iver  imaging  was  used.
SWE  was  ﬁrst  performed  in  the  segment  5  of  the  liver.he  right  arm  was  placed  in  maximum  abduction  to  enlarge
he  space  between  the  ribs.  During  SWE  acquisition,  the
atient  was  asked  to  stop  breathing  during  5  seconds.  The
lastographic  acquisition  was  repeated  5  times  for  each
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(Shear  wave  elastography  
patient.  For  each  acquisition,  real-time  SWE  2D  color  map
of  the  stiffness  (in  kPa)  was  frozen  after  a  stabilization  of  at
least  3  seconds.  The  placement  of  the  SWE  color  map  could
be  moved,  enabling  an  extended  visual  evaluation  of  liver
stiffness.  The  size  of  the  SWE  color  box  was  3  ×  4  cm.  The
measurements  were  performed  in  a  1.6  to  3  cm-diameter
region  of  interest  (ROI),  within  the  chosen  liver  biopsy
area.  The  subcapsular  region  was  avoided  because  rever-
beration  artifacts  are  often  found  beneath  the  capsule  of
Glisson.  Similarly,  perivascular  areas  were  avoided  because
they  may  alter  liver  stiffness  estimate.  The  shear  wave
images  were  qualitatively  evaluated  off-line  on  a  computer
by  two  radiologists,  with  more  than  2  years  of  experience
in  SWE  imaging.  The  assessment  was  made  with  the  opera-
tors  blinded  to  the  histological  diagnosis.  An  acquisition  was
considered  to  be  successful  if  2  or  3  of  these  following  crite-
ria  were  fulﬁlled:  the  SWE  color  box  ﬁlled  of  more  than  2
thirds  of  the  total  SWE  box  surface,  the  elastographic  signal
within  the  vessels  missed,  the  minimal  stiffness  was  superior
to  0.2  kPa  in  the  ROI  as  previously  recommended  [16].  For
each  patient,  stiffness  was  deﬁned  as  the  median  of  several
SWE  successful  measurements.  In  a  subgroup  of  randomly
selected  patients,  5  additional  acquisitions  were  also  per-
formed  by  a  third  physician,  blinded  to  the  previous  results
in  order  to  study  the  inter-observer  reproducibility.
Liver  biopsy  was  performed  immediately  after  SWE,
under  ultrasound  guidance,  through  the  same  intercostal
space  and  in  the  same  area  of  segment  5  as  in  SWE.  A  biopsy
gun  16G  Magnum® (Bard  Ltd,  UK)  was  used  to  collect  histo-
logical  samples.  To  be  eligible  for  analysis,  biopsy  samples
had  to  be  at  least  20  mm  long  and  to  contain  at  least  11
portal  tracts  as  recommended  by  the  American  Association
of  Study  of  Liver  Disease  guidelines  [17],  except  for  obvious
cirrhosis.  In  case  of  a  small  sample  size,  repeat  liver  biopsy
was  immediately  performed.  The  tissue  sample  was  then
processed  according  to  the  standard  techniques,  ﬁxed  in
formaldehyde  and  embedded  in  parafﬁn.  Four  m-thick  sec-
tions  were  cut.  One  section  was  stained  with  hematoxylin,
eosin  and  saffron  for  complete  histopathological  examina-
tion  and  activity  grading.  Another  section  was  stained  with
Picrosirius  Red  for  ﬁbrosis  staging.  Biopsies  were  scored
according  to  the  METAVIR  system  [18]  by  a  single  pathol-
ogist  blinded  to  SWE  results.  Liver  activity  was  graded
as  A0  (absence  of  inﬂammation),  A1  (small),  A2  (moder-
ate),  A3  (severe).  Liver  ﬁbrosis  was  scored  as:  F0,  absent;
F1,  enlarged  ﬁbrotic  portal  tract;  F2,  periportal  or  initial
portal-portal  septa  with  intact  architecture;  F3,  architec-
tural  distortion  but  no  obvious  cirrhosis  and  F4,  cirrhosis.
Additionally,  steatosis  was  assessed  using  the  Kleiner  scoring
system:  S0:  <  5%,  S1:  5—33%,  S2:  33—66%,  S3:  >  66%  [19].
Subgroup analysis
All  patients  who  underwent  one  successful  TE  within  one
month  prior  to  liver  biopsy  were  included  in  a  sub-study.
TE  was  performed  by  trained  and  experienced  technicians.
The  probe  was  applied  perpendicularly  on  the  skin,  in  the
right  intercostal  space  of  the  midaxillary  line,  in  the  area
used  for  the  biopsy.  Ten  acquisitions  were  recorded  for  each
patient.  A  successful  acquisition  was  deﬁned  as  an  interquar-
tile  range  of  less  than  30%  of  the  median  elasticity  and  a
success  rate  of  more  than  60%  [20].
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In  patients  who  had  successful  SWE  and  TE  acquisitions,
he  percentage  of  ﬁbrosis  was  assessed  by  histomorphom-
try  on  the  liver  biopsy  samples.  The  area  of  ﬁbrosis  was
tudied  using  one  4  m-thick  tissue  section  of  formalin-
xed,  parafﬁn-embedded  liver  tissue  stained  with  Sirius  red
nd  lightly  counterstained  with  hematoxylin.  Image  analy-
is  was  performed  on  an  optical  microscope  (Eclipse  E400,
ikon,  Japan)  supplied  with  a  scanning  device  and  with
 dedicated  software  (Histolab,  Microvision  Instruments,
vry,  France)  aimed  to  digitize  images  of  the  complete
ection.  The  percentage  of  ﬁbrosis,  corresponding  to  the
ollagen  proportionate  area,  was  determined,  as  previously
escribed  [21]:
the  area  of  ﬁbrosis  was  determined  by  measuring  the  sur-
face  speciﬁcally  stained  with  Sirius  red;
the  total  area  of  the  tissue  sample  was  determined  after
manual  contouring  of  the  whole  biopsy  sample;
the  percentage  of  ﬁbrosis  was  the  ratio  between  the  sur-
face  of  ﬁbrosis  and  the  surface  of  the  whole  tissue  sample.
No  distinction  was  made  between  portal  and  peripor-
al  ﬁbrosis,  perisinusoidal  ﬁbrosis  and  perivenular  ﬁbrosis.
 quality  control  was  performed  by  a single  supervisor  on  all
mages  used  for  analysis.
tatistical analysis
he  diagnostic  performances  of  SWE  and  their  95%  conﬁ-
ent  interval  (95%  CI)  were  assessed  using  the  areas  under
he  receiver  operating  characteristic  curves  (AUROC)  as
ariables  for  comparison.  Several  ﬁbrosis  thresholds  were
valuated:  F0—F1  versus  F2  to  F4  (≥  F2)  for  signiﬁcant  ﬁbro-
is,  F0  to  F2  versus  F3  to  F4  (≥  F3)  for  advanced  ﬁbrosis,  F0
o  F3  versus  F4  (F4)  for  cirrhosis.  For  each  threshold,  the
ptimal  stiffness  cut-off  was  estimated  in  maximizing  the
ouden’s  index  deﬁned  as  sensitivity  +  speciﬁcity-1.  Further
nalyses  were  performed  using  the  Obuchowski  measures
22]. This  measure  summarizes  all  pairwise  comparisons
f  ﬁbrosis  stages  deﬁned  by  liver  biopsy,  with  a  weighting
cheme  and  a  penalty  function.  Comparison  between  the
buchowski  measures  was  made  using  DeLong  et  al.  method
23].
The  relationship  between  stiffness  and  METAVIR  ﬁbrosis
as  described  according  to  the  steatosis  and  METAVIR  activ-
ty  scores.  The  correlation  between  SWE  and  steatosis,  SWE
nd  METAVIR  grade  (inﬂammation),  SWE  and  METAVIR  stage
ﬁbrosis)  was  evaluated  using  the  Spearman’s  rank  coefﬁ-
ient  and  multivariate  regression  analysis.
Inter-observer  reproducibility  was  studied  using  an  intr-
class  correlation  coefﬁcient  (ICC).
In  the  sub-study,  AUROC  calculated  from  SWE  and  TE
iagnostic  performances  were  compared  within  the  same
hresholds  as  the  whole  study.  Correlation  between  stiff-
ess  measured  by  SWE  or  TE  and  the  total  ﬁbrosis  area  were
ssessed  using  the  Spearman  rank  coefﬁcient.  Statistical  cal-
ulations  were  performed  using  Stata  statistical  package
StataCorp  LP,  College  Station,  TX).esults
ne  hundred  and  seventy  consecutive  patients  were
ncluded  in  this  study  between  September  2010  and  May
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012.  SWE  failure  was  observed  in  18  of  the  170  patients
10.5%).  The  causes  of  failure  were  poor  acoustic  windows
n  14  patients  (78%)  including  9  patients  with  a  BMI  above
0  kg/m2 and  excessive  tissue  movement  in  4  patients  (22%)
ue  to  breathing.  Moreover,  four  patients  were  excluded
ue  to  poor  liver  biopsy  sampling.  Therefore,  148  patients
ere  ﬁnally  included  in  the  analysis.  They  were  95  men
nd  53  women  with  a  mean  age  of  54.3  years  ±  13.2  (SD)
Table  1).
o
t
p
Table  1 Baseline  characteristics  of  148  patients  included  in  th
Characteristics  
Male  gender  
Age  (years)  
BMI  (kg/m2)  
AST  (IU/L)  
ALT  (IU/L)
Alkaline  phosphatase  (IU/L)
GGT  (IU/L)
Total  bilirubin  (M/L)
Serum  albumin  (g/L)
Platelets  count  (103/mm3)
Prothrombin  time  (%)
Liver  transplantation
Chronic  liver  condition  in  native  liver
Non-alcoholic  steatohepatitis
Viral  chronic  hepatitis  B  or  C
Alcoholic  liver  disease
Auto-immune  hepatitis  
Chronic  biliary  disease  
Other  
Fibrosis  score  (METAVIR)
F0—F1  
F2  
F3  
F4  
Qualitative variables are expressed as raw numbers (%) and quantitat
index; AST: aspartate aminotransferase; ALT: alanine aminotransferase
igure 1. Receiver Operating Characteristic curves for shear wave el
F0—F1 versus F2 to F4: ≥ F2), (b) advanced ﬁbrosis (F0 to F2 versus F3 tA.  Guibal  et  al.
According  to  ﬁbrosis  thresholds,  AUROCs  ranged  between
.90  (95%CI:  0.85—0.95)  and  0.99  (95%CI:  0.96—0.99)  and
ere  statistically  signiﬁcant  (Fig.  1).  The  optimal  stiffness
ut-off  to  assess  signiﬁcant  ﬁbrosis,  advanced  ﬁbrosis  and
irrhosis  were,  respectively,  8.8  kPa,  11.5  kPa  and  18.1  kPa.
hatever  the  ﬁbrosis  thresholds,  sensitivity  and  speciﬁcity
f  SWE  were  above  80%  and  increased  with  the  ﬁbrosis
hreshold.  Same  trends  were  shown  for  positive  and  negative
redictive  values  (Table  2).
e  main  analysis  and  55  patients  included  in  the  sub-study.
Total
n  =  148
Sub-study
n  =  55
95  (64.2%)  34  (61.9%)
54.3  (±13.2)  49.6  (±14)
24.9  (±4.3)  24.7  (±3.8)
41.9  (±24)  44.9  (±27.6)
48.7  (±29.8)  57.4  (±36.8)
104.8  (±40.1) 103.2  (±46.3)
158.1  (±152)  152.7  (±148.9)
16.6  (±12) 11.7  (±6.2)
40.8  (±3.6)  41.6  (±4.1)
183 (±60.1) 195.2  (±60.9)
90.1  (±13.5) 96.1  (±6.7)
57  (±38.5) 21  (±38.3)
30  (20.3%) 13  (23.6%)
22 (14.8%) 9  (16.4%)
17  (11.5%) 2  (3.6%)
4  (2.7%)  2  (3.6%)
4  (2.7%)  2  (3.6%)
14  (9.5%)  6  (10.9%)
81  (54.7%)  34  (61.8%)
22  (14.9%)  7  (12.7%)
15  (10.1%)  8  (14.6%)
30  (20.3%)  6  (10.9%)
ive variable as mean value ± standard deviation. BMI: body mass
; GGT: gamma glutamyltransferase.
astography for different ﬁbrosis thresholds: (a) signiﬁcant ﬁbrosis
o F4: ≥ F3), (c) cirrhosis (F0 to F3 versus F4) (n = 148).
Shear  wave  elastography  95
Table  2  Diagnosis  accuracy  of  share  wave  elastography  and  optimal  stiffness  cut-off  according  level  of  ﬁbrosis  (n  =  148).
F  ≥  2  F  ≥  3  F  =  4
Optimal  stiffness  cut-off  (kPa)  8.8  11.5  18.1
Sensitivity  85.1  (74.3—92.6)  88.9  (75.9—96.3)  93.3  (77.9—99.2)
Speciﬁcity  82.7  (72.7—90.2) 90.3  (82.9—95.2) 98.3  (94.0—99.8)
Positive  predictive  value 80.3  (69.0—88.8) 80.0  (66.1—90.1) 93.3  (77.6—99.2)
Negative  predictive  value  87.0  (77.3—93.6)  94.9  (88.5—98.3)  98.3  (94.0—99.8)
Positive  likelihood  ratio  4.9  (4.3—5.7)  9.16  (8.1—10.3)  55.1  (49.9—60.8)
Negative  likelihood  ratio  0.18  (0.09—0.4)  0.12  (0.04—0.3)  0.07  (0.01—0.5)
Signiﬁcant ﬁbrosis: ≥ F2 (F0—F1 versus F2 to F4), advanced ﬁbrosis: ≥ F3 (F0 to F2 versus F3 to F4), cirrhosis: F4 (F0 to F3 versus F4).
Values of sensitivity, speciﬁcity, positive predictive value and negative predictive value are in percentage (95% conﬁdence interval).
Table  3  Diagnostic  performances  of  SWE  using  the
Obuchowski  method  in  148  patients.
Estimate  Standard  error
wAUC  0.953  0.007
Details  between  all  pair
F0  versus  F1  0.593  0.065
F0  versus  F2  0.807  0.061
F0  versus  F3  0.943  0.030
F0  versus  F4  0.996  0.004
F1  versus  F2  0.742  0.064
F1  versus  F3  0.899  0.046
F1  versus  F4  0.996  0.004
F2  versus  F3  0.765  0.086
F2  versus  F4  0.989  0.011
F3  versus  F4  0.947  0.032The  median  stiffness  was  7.0  kPa  (IQR:  6.0;  8.3)  for
F0—F1,  9.5  kPa  (IQR:  7.8;  11.4)  for  F2,  13.0  kPa  (IQR:  10.4;
16.7)  for  F3  and  25.8  kPa  (IQR:  21.7;  34.5)  for  F4,  and  was
signiﬁcantly  associated  with  METAVIR  ﬁbrosis  whatever  the
ﬁbrosis  score  (F0—F1  vs.  F2,  P  =  0.0001;  F2  vs.  F3,  P  =  0.04;
F3  vs.  F4,  P  =  0.0002)  (Fig.  2).
The  global  Obuchowski  measure  was  signiﬁcantly  high
(0.953  ±  0.007)  (Table  3).
The  relationships  between  the  METAVIR  ﬁbrosis  and  stiff-
ness  did  not  signiﬁcantly  differ  according  to  steatosis  or
METAVIR  activity  (Fig.  3).  Nevertheless,  at  univariate  anal-
ysis,  median  stiffness  was  signiﬁcantly  associated  with
METAVIR  ﬁbrosis  (r  =  0.758,  P  <  0.0001)  or  activity  (r  =  0.252,
P  <  0.01)  but  not  with  steatosis  (r  =  0.103,  P  =  0.24),  but
at  multivariate  analysis,  METAVIR  ﬁbrosis  remained  the
only  independent  variable  associated  with  median  stiffness
(r  =  0.697;  P  <  0.001).
Twenty-ﬁve  patients  were  included  in  the  inter-observer
reproducibility  study.  The  ICC  was  0.92  (95%  CI:  0.81—0.96).
Figure 2. Box and whisker plots of values obtained with SWE
measurements, according to each METAVIR ﬁbrosis stage. Each box
represents the interquartile range (from the 25th to the 75th per-
centile) within which 50% of the elasticity values are represented.
The line crossing horizontally each box represents the median. The
error bars show the minimum and maximum non-extremes values
(median values). The median values (in kPa) were for F0—F1: 7.0
(IQR = 6.0—8.3), F2: 9.5 (IQR = 7.8—11.4), F3: 13.0 (IQR = 10.4—16.7)
and F4: 25.8 (IQR = 21.7—34.5).
wAUC indicates the Obuchowski measure of the AUC.
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mong  the  148  patients,  55  patients  had  additional  his-
omorphometrical  assessment  of  ﬁbrosis  percentage  and  a
uccessful  TE  acquisition.  Main  characteristics  of  this  sub-
tudy  population  did  not  differ  than  those  of  the  whole  study
opulation  (Table  1).
No  signiﬁcant  differences  on  AUROCs  were  found
etween  TE  and  SWE,  according  to  the  ﬁbrosis  thresholds
P  =  0.75,  0.62  and  0.21  respectively  for  ≥  F2,  ≥  F3  and  F4)
Fig.  4).  Sensitivity,  speciﬁcity,  positive  and  negative  predic-
ive  values  did  not  differ  regarding  the  conﬁdence  intervals,
lthough  ﬁbrosis  thresholds  were  not  the  same  between  the
wo  techniques  (Table  4).  Liver  stiffness  was  signiﬁcantly
ssociated  with  the  percentage  of  ﬁbrosis  for  SWE  (r  =  0.77;
5%CI:  0.63—0.86;  P  <  0.0001)  and  for  TE  (r  =  0.65;  95%CI:
.47—0.78;  P  <  0.01)  (Fig.  5).
iscussionur  results  suggest  that  SWE  is  an  accurate  and  reproducible
on-invasive  method  to  assess  liver  ﬁbrosis,  especially  for
he  diagnosis  of  signiﬁcant  ﬁbrosis  in  patients  with  various
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Figure 3. Box and whisker plots of SWE values for each METAVIR
stage in relation to the degree of (a) steatosis and (b) necrotico-
inﬂammatory activity (METAVIR grade) (n = 148). The central box
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he box represents median value. Bars represent minimum and max-
mum non-extreme values.auses  of  liver  ﬁbrosis.  Moreover,  liver  stiffness  assessed  by
WE  is  well  correlated  to  liver  biopsy  using  METAVIR  score.
his  is  the  ﬁrst  study  that  compares  the  liver  stiffness  esti-
ated  by  SWE  and  TE  with  ﬁbrosis  assessed  both  by  the
w
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igure 4. ROC curves for SWE and TE for different ﬁbrosis thresholds:
brosis (F0 to F2 versus F3 to F4: ≥ F3), (c) cirrhosis (F0 to F3 versus F4)A.  Guibal  et  al.
emi-quantitative  METAVIR  score  and  a quantitative  histo-
ogical  score  estimating  percent  ﬁbrosis.
The  AUROC  is  widely  used  to  measure  the  diagnostic  per-
ormance  of  non-invasive  ﬁbrosis  techniques.  Nevertheless,
ts  use  needs  a  binary  gold  standard  whereas  ﬁbrosis  staging
s  based  on  the  ﬁve-stage  METAVIR  score.  This  difference
mplies  that  ﬁbrosis  stages  have  to  be  aggregated  into  2
roups,  a  process  that  can  lead  to  discordant  conclusions,
epending  on  how  the  groups  are  aggregated.  Moreover,  in
ase  of  spectrum  bias  [24]  (i.e.  when  extreme  stages  of
brosis  (F0  and  F4)  are  over-represented  in  the  study  pop-
lation)  the  sensitivity  and  speciﬁcity  of  the  test  will  be
rtiﬁcially  increased  as  compared  to  the  general  popula-
ion  [20].  To  overcome  these  issues  in  case  of  ordinal  gold
tandards,  the  use  of  the  Obuchowski  multinomial  meas-
res  was  suggested  [22].  In  our  study,  the  use  of  these
easures  strengthened  the  overall  performance  of  SWE  as
ssessed  by  AUROCs  analysis,  although  they  underlined  a
ower  performance  when  discriminating  between  F0  and  F1
16]. Fortunately,  the  potential  misclassiﬁcation  between  F0
nd  F1  has  little  impact  on  the  management  of  patients  with
iver  ﬁbrosis.
In  our  study,  the  SWE  performances  according  to  ﬁbrosis
hresholds  using  METAVIR  score  were  similar  to  those  of  pre-
ious  studies  in  patients  with  both  various  [25]  or  speciﬁc
brosis  etiologies  such  as  HCV  [14]  or  HBV  [15]  infections.
owever,  our  optimal  stiffness  cut-off  values  were  slightly
igher  than  those  in  these  studies  [14,15,25]. In  this  regard,
e  found  8.8  kPa  in  our  study  for  signiﬁcant  ﬁbrosis  versus
.1—8.0  kPa  in  other  studies  [14,15,25], 11.5  kPa  in  our  study
or  severe  ﬁbrosis  versus  7.9—8.9  kPa  in  other  studies  and
8.1  kPa  for  cirrhosis  versus  10.1—10.7  kPa  in  other  studies.
ariability  in  METAVIR  scoring  might  explain  some  of  these
ifferences,  especially  for  signiﬁcant  and  severe  ﬁbrosis  [2].
e  also  believe  that  the  METAVIR  scale  itself  might  con-
ribute  to  explain  a  higher  cirrhosis  cut-off.  Whereas  each
brosis  stage  matches  with  a  well-deﬁned  level  of  ﬁbrosis,
he  cirrhosis  stage  includes  all  levels  of  cirrhosis  severity
ithout  upper  limit.  Thus,  the  optimal  stiffness  cut-off  of
irrhosis  would  be  highly  related  to  the  study  population:
igher,  when  mainly  severe  cirrhosis  would  be  included  in
he  study,  lower,  when  ‘‘overt  cirrhosis’’  would  be  excluded
 (a) signiﬁcant ﬁbrosis (F0—F1 versus F2 to F4: ≥ F2), (b) advanced
 (n = 55).
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Table  4  Optimal  stiffness  cut-off  and  diagnosis  accuracy  of  share  wave  elastography  (SWE)  and  transient  elastography
(TE),  according  to  level  of  ﬁbrosis  (n  =  55).
Procedure  F  ≥  2  F  ≥  3  F  =  4
Optimal  stiffness  cut-off  (kPa)
SWE  8.5  11.5  15.8
TE  7.3  8.6  11.8
Sensitivity
SWE  90.5  (69.6—98.8)  78.6  (49.2—95.3)  100  (54.1—100)
TE  85.7  (63.7—97.0)  85.7  (57.2—98.2)  100  (54.1—100)
Speciﬁcity
SWE  79.4  (62.1—91.3)  97.6  (87.1—99.9)  98.0  (89.1—99.9)
TE  88.2  (72.5—96.7)  90.2  (76.9—97.3)  87.8  (75.2—95.4)
Positive  predictive  value
SWE  73.1  (52.2—88.4)  91.7  (59.7—99.8)  85.7  (42.1—99.6)
TE  81.8  (59.7—94.8)  75.0  (46.6—93.1)  50.0  (21.1—78.9)
Negative  predictive  value
SWE  93.1  (76.8—99.2)  93.0  (80.9—98.5)  100  (92.6—100)
TE  90.9  (75.3—98.1)  94.9  (82.7—99.4)  100  (91.6—100)
Positive  likelihood  ratio
SWE  4.4  (2.2—8.6)  32.2  (4.6—227.6)  49.0  (7.0—340.9)
TE  7.3  (5.9—9.0)  8.8  (6.9—11.1)  8.17  (7.4—9.1)
Negative  likelihood  ratio
SWE  0.12  (0.03—0.5)  0.22  (0.08—0.6)  0
TE  0.16  (0.04—0.7)  0.16  (0.03—0.8)  0
Values of sensitivity, speciﬁcity, positive predictive value and negative predictive value are in percentage (95% conﬁdence interval).
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o
aas  in  the  study  by  Ferraioli  et  al.  [14],  with  a  median  stiff-
ness  for  cirrhosis  of  15.6  kPa  (range:  8.0—22.5)  in  their  study
versus  25.8  kPa  (range:  10.5—54.5)  in  our  study.  This  also
explains  the  differences  of  cut-off  for  cirrhosis  between  our
main  population  and  those  of  the  sub-study.
Normal  liver  tissue  contains  5.5  mg  of  collagen  per  gram
of  parenchyma,  while  a  cirrhotic  liver  contains  more  than
l
a
i
Figure 5. Correlation between total ﬁbrosis area and liver stiffness m
SWE and (b) TE (n = 55). Stiffness is signiﬁcantly associated with the perc0  mg/g  [26].  Semi-quantitative  histological  scores  like  the
ETAVIR  score  are  markers  of  ﬁbrosis  architecture  with-
ut  an  absolute  quantitative  estimate  of  liver  ﬁbrosis.  The
ddition  of  a quantitative  assessment  liver  ﬁbrosis  from
iver  biopsy  could  reduce  some  of  the  reader  variability
nd  misclassiﬁcation  associated  semi-quantitative  histolog-
cal  scores.
easurements with details of the METAVIR stages obtained with (a)
entage of ﬁbrosis for SWE and TE.
9A
s
t
[
s
r
o
s
t
o
d
r
r
p
f
t
d
p
t
e
c
b
l
t
t
p
s
u
A
T
w
D
T
i
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[8  
Consistent  with  the  results  of  prior  studies  using  TE  [27],
RFI  [28]  or  even  SWE  [14,29]  our  results  support  that  steato-
is  has  no  major  effect  on  stiffness  measurements.  Although
he  role  of  inﬂammation  on  stiffness  measurements  with  TE
30],  ARFI  [31]  or  SWE  [14]  is  debated,  no  correlation  was
hown  in  our  study.
In  our  study,  we  observed  a  failure  rate  similar  to  those
eported  with  SWE  [14,16,25,32]  or  with  TE  [8,9,33].  Causes
f  failure  of  SWE  were  similar  to  those  reported  in  other
tudies  [14,16,25,32].  In  case  of  high  BMI,  SWE  does  not  seem
o  improve  the  success  rate  of  a  liver  stiffness  estimate  over
ther  share  wave  techniques.
Whereas  SWE  has  an  excellent  inter-observer  repro-
ucibility  as  previously  shown  [15,32],  the  intra-observer
eproducibility  was  not  evaluated.  SWE  has  shown  improved
eliability  and  repeatability  [29,32]  over  TE.
Although  our  study  has  evaluated  SWE  in  a  relatively  small
opulation,  we  believe  that  it  is  representative  of  patients
ollowed  for  different  causes  of  liver  ﬁbrosis  in  clinical  rou-
ine.  As  liver  transplantation  is  known  to  inﬂuence  stiffness
uring  the  early  weeks  [29],  we  excluded  patients  trans-
lanted  for  less  than  6  months.
Our  study  has  some  limitations.  Of  these,  we  did  not  study
he  inﬂuence  of  liver  viscosity  on  the  results  of  SWE.  How-
ver,  this  was  recently  done  by  Defﬁeux  et  al.  who  reported  a
orrelated  between  viscosity  and  the  degree  of  liver  ﬁbrosis,
ut  not  with  steatosis  or  disease  activity  [34].
In  conclusion,  SWE  might  be  a  useful  tool  to  screen  for
iver  ﬁbrosis  in  the  general  population  during  a  conven-
ional  ultrasound  examination,  especially  when  laboratory
ests  and  ultrasound  examination  are  negative  despite  the
otential  underlying  ﬁbrosis  [35].  However,  epidemiological
tudies  are  needed  to  fully  investigate  the  performance  and
tility  of  SWE  in  this  setting.
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